Ivermectin: facts and science are in its favour – Dr Rapiti

Loading player...
In August 2021, BizNews conducted a panel discussion with Professor Colleen Aldous, Dr Nathi Mdladla and Dr Pinky Ngcakani – all of whom are strongly in favour of ivermectin. The discussion was published on BizNews TV on YouTube and for a year, it managed to evade the YouTube censorship police. Last week, Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects showed that Regular Use of Ivermectin as Prophylaxis for COVID-19 led to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner. First thing this morning, BizNews received notification of a strike on our BizNews TV YouTube channel on account of the ivermectin panel discussion, which was taken down. The timing appears too odd for coincidence. What may be more realistic is that the World Health Organisation, which is in close ‘cahoots’ with YouTube, is doing a sweep of all pro-ivermectin content. This is the original ivermectin panel discussion podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices
5 Sep 2022 11AM English South Africa Investing · Business News

Other recent episodes

BizNews Edge: Why the IRR's John Endres is more bullish on SA than Britain

John Endres, CEO of the Institute for Race Relations, tells BizNews that the elite consensus defending BEE is cracking, even as its beneficiaries defend it loudest. He points to the Starlink saga - blocked partly over empowerment shareholding while a pricier, slower rival wins state favour - as proof the…
13 Jul 8AM 24 min

A world-first: the bond that pays out when nature wins

In this BizNews interview, Irakli Rekhviashvili sits down with the three people behind FirstRand's R2.5 billion Cape Water Performance-Based Bond, the first time a commercial bank anywhere in the world has tied a bond's payout to nature. The Nature Conservancy's Louise Stafford traces it to 2018, when Cape Town's dams…
12 Jul 8AM 15 min